T Cell Acute Lymphoblastic Leukemia Therapeutics
1. Arranon patent expiration
Treatment: Treatment of patients with t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens; Treatment of patients with t-ce...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5747472 | SANDOZ | Therapeutic methods for using ARA-G derivatives |
Feb, 2013
(12 years ago) | |
| US5424295 | SANDOZ | 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
Jun, 2017
(8 years ago) | |
| US5492897 | SANDOZ | Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
Feb, 2013
(12 years ago) | |
| US5821236 | SANDOZ | Tumor treatment with arabinofuranosyl purine derivatives |
Feb, 2013
(12 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 28, 2012 |
Drugs and Companies using NELARABINE ingredient
Market Authorisation Date: 28 October, 2005
Dosage: INJECTABLE
More Information on Dosage
ARRANON family patents
